



HAL
open science

Fibroblast growth-factor-21 is currently a weak biomarker for identifying mitochondrial and non-mitochondrial inborn errors of metabolism

Josef Finsterer, Sinda Zarrouk-Mahjoub

► To cite this version:

Josef Finsterer, Sinda Zarrouk-Mahjoub. Fibroblast growth-factor-21 is currently a weak biomarker for identifying mitochondrial and non-mitochondrial inborn errors of metabolism. *Molecular Genetics and Metabolism Reports*, 2018, 14, pp.1-2. 10.1016/j.ymgmr.2017.10.005 . pasteur-02017153

HAL Id: pasteur-02017153

<https://riip.hal.science/pasteur-02017153>

Submitted on 13 Feb 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License



Correspondence

Fibroblast growth-factor-21 is currently a weak biomarker for identifying mitochondrial and non-mitochondrial inborn errors of metabolism



ARTICLE INFO

Keywords:

Mitochondrial
mtDNA
Phenotype
Genotype
Lymphocytes
FGF21

We read with interest the article by Kirmse et al. about fibroblast growth-factor-21 (FGF21) serum levels in a cohort of patients with an inborn error of metabolism (IEM) [1]. FGF21 levels were increased in IEM patients but highly variable in the various subgroups [1]. We have the following comments and concerns.

In the methods section it is mentioned that 42 patients with an IEM were investigated. However, in the result section only 38 IEM patients are mentioned. Furthermore, in figure 1 five patients with a mitochondrial disorder (MID) are presented but in the text only 4 with a MID are mentioned [1]. How to explain these discrepancies?

The authors mention that FGF21 is particularly increased in patients with a MID manifesting as myopathy [1]. How many of the four respectively five patients with a MID had myopathy? How many of the non-mitochondrial patients had muscle involvement?

According to figure 1 there were five patients from five different subgroups with FGF21 levels > 1000 pg/mL [1]. What did these five patients have in common? Myopathy? Interestingly, MID patients did not show FGF21 levels > 1000 pg/mL.

Serum lactate is regarded as a biomarker of MIDs [2]. Was serum lactate correlated with FGF21 levels at least in the mitochondrial IEM group (MITO, UCD, OA, FAO)?

Since FGF21 levels may be elevated due to various different causes, elevation of FGF21 in MIDs is non-specific. Did the authors consider causes other than “inefficient energy metabolism biochemically similar to starvation” to explain elevated FGF21 values?

Did FGF21 levels increase with age or with disease progression? Provision of age in the included probands would be helpful.

Overall, this interesting study would profit from a more homogenous study population from clarification if FGF21 was particularly elevated among those which had myopathy, and if FGF21 values were correlated with serum lactate values.

Conflicts of interest

There are no conflicts of interest.

Funding

No funding was received.

Author contribution

JF: design, literature search, discussion, first draft, SZ-M: literature search, discussion, critical comments.

References

- [1] B. Kirmse, J. Cabrera-Luque, O. Ayyub, K. Cusmano, K. Chapman, M. Summar, Plasma fibroblast growth factor-21 levels in patients with inborn errors of metabolism, *Mol. Genet. Metab. Rep.* 13 (2017) 52–54.

- [2] J. Finsterer, E. Milvay, Lactate stress testing in 155 patients with mitochondriopathy, *Can. J. Neurol. Sci.* 29 (2002) 49–53.

<http://dx.doi.org/10.1016/j.ymgmr.2017.10.005>

Received 19 October 2017; Accepted 20 October 2017

Available online 26 October 2017

2214-4269/© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Josef Finsterer*

Krankenanstalt Rudolfstiftung, Vienna, Austria

E-mail address: ffigs1@yahoo.de

Sinda Zarrouk-Mahjoub

University of Tunis El Manar and Genomics Platform, Pasteur Institute of Tunis, Tunisia

* Corresponding author at: Postfach 20, 1180 Vienna, Austria.

¹ Both authors contributed equally.